§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇺🇦Ukraine	🇺🇸United States
Authority & dossier
Regulatory authority	MOZ / SEC	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	—
Lead pathway (timeline & fees) — National Procedure (Standard) · New Drug Application — 505(b)(1)
Pathway name	National Procedure (Standard)	New Drug Application — 505(b)(1)
Approval timeline	210–365 days	304–365 days
Application fee	UAH 100,000	USD 4,310,002
Annual renewal	UAH 0	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	Each MA holder must designate a Qualified Person for Pharmacovigilance (Upovnovazhena Osoba z Farmakonahliadu) — Ukraine-resident, registered with SEC, accountable for ADR reporting via the SEC AISF (Automated Information System for Pharmacovigilance) electronic system. PSURs aligned to ICH E2C(R2) submitted to SEC per the EURD-equivalent national list.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Wartime Simplified Procedure (Resolution 376, 2022), Abridged Procedure (Order No. 426), Orphan Drug Designation +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per MOZ Order No. 460 (closely aligned with EU Regulation 1234/2008) into Type IA / IAIN (notification), Type IB (tell-wait-do), Type II (prior approval), and Extensions of registration.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Initial registration certificate valid for 5 years; subsequent renewal grants indefinite validity (mirroring EU framework), subject to favourable benefit/risk and submission of renewal documentation.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	SEC's Department of Post-Authorisation Surveillance coordinates national pharmacovigilance through the AISF (Automated Information System for Pharmacovigilance) electronic system. Ukraine is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 2002). MAHs must submit PSURs aligned to ICH E2C(R2), report serious unexpected ADRs within 15 days, and maintain a Risk Management Plan (RMP) for new active substances and vaccines. EU GVP modules are progressively implemented.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–90 days	30–30 days
GCP standard	ICH E6(R2) GCP (national MOZ Order No. 690); progressive alignment with EU Clinical Trials Regulation 536/2014; Helsinki Declaration	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	SEC Department of Health Technology Assessment performs HTA for inclusion of medicines in the National Essential Medicines List (NEML) and the Affordable Medicines reimbursement programme. NSZU operationalises reimbursement decisions.	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

UkraineMOZ / SEC
United StatesFDA

English submissions

UkraineYes
United StatesYes

CTD accepted

UkraineYes
United StatesYes

eCTD accepted

UkraineYes
United StatesYes

Reliance pathway

UkraineAvailable
United StatesNone

Reference agencies

UkraineFDA (US), EMA, MHRA (UK), Health Canada +4
United States—

Lead pathway (timeline & fees) — National Procedure (Standard) · New Drug Application — 505(b)(1)

Pathway name

UkraineNational Procedure (Standard)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Ukraine210–365 days
United States304–365 days

Application fee

UkraineUAH 100,000
United StatesUSD 4,310,002

Annual renewal

UkraineUAH 0
United StatesUSD 416,734

Local representative

UkraineRequired
United StatesNot required

Local manufacturing

UkraineNot required
United StatesNot required

GMP inspection

UkraineRequired
United StatesRequired

MAH & local presence

Local entity required

UkraineYes
United StatesNo

Local responsible person

UkraineYes
United StatesYes

RP role

UkraineEach MA holder must designate a Qualified Person for Pharmacovigilance (Upovnovazhena Osoba z Farmakonahliadu) — Ukraine-resident, registered with SEC, accountable for ADR reporting via the SEC AISF (Automated Information System for Pharmacovigilance) electronic system. PSURs aligned to ICH E2C(R2) submitted to SEC per the EURD-equivalent national list.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Ukraine4 designations
United States6 designations

Examples

UkraineWartime Simplified Procedure (Resolution 376, 2022), Abridged Procedure (Order No. 426), Orphan Drug Designation +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

UkraineVariations classified per MOZ Order No. 460 (closely aligned with EU Regulation 1234/2008) into Type IA / IAIN (notification), Type IB (tell-wait-do), Type II (prior approval), and Extensions of registration.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

UkraineInitial registration certificate valid for 5 years; subsequent renewal grants indefinite validity (mirroring EU framework), subject to favourable benefit/risk and submission of renewal documentation.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

UkraineSEC's Department of Post-Authorisation Surveillance coordinates national pharmacovigilance through the AISF (Automated Information System for Pharmacovigilance) electronic system. Ukraine is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 2002). MAHs must submit PSURs aligned to ICH E2C(R2), report serious unexpected ADRs within 15 days, and maintain a Risk Management Plan (RMP) for new active substances and vaccines. EU GVP modules are progressively implemented.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

UkraineAvailable
United StatesAvailable

Compassionate Use

UkraineAvailable
United StatesAvailable

Emergency Import

UkraineAvailable
United StatesAvailable

Parallel Import

UkraineNot permitted
United StatesNot permitted

Clinical trials

CTA approval

UkraineRequired
United StatesRequired

Ethics approval

UkraineYes
United StatesYes

CTA timeline

Ukraine60–90 days
United States30–30 days

GCP standard

UkraineICH E6(R2) GCP (national MOZ Order No. 690); progressive alignment with EU Clinical Trials Regulation 536/2014; Helsinki Declaration
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

UkraineRegulated
United StatesFree pricing

Reference pricing

UkraineYes
United StatesNo

HTA required

UkraineYes
United StatesNo

HTA body

UkraineSEC Department of Health Technology Assessment performs HTA for inclusion of medicines in the National Essential Medicines List (NEML) and the Affordable Medicines reimbursement programme. NSZU operationalises reimbursement decisions.
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding